Katz Jason N, Stebbins Amanda L, Alexander John H, Reynolds Harmony R, Pieper Karen S, Ruzyllo Witold, Werdan Karl, Geppert Alexander, Dzavik Vladimir, Van de Werf Frans, Hochman Judith S
University of North Carolina School of Medicine, Chapel Hill, NC 27599-7875, USA.
Am Heart J. 2009 Oct;158(4):680-7. doi: 10.1016/j.ahj.2009.08.005.
Little is known about predictors of survival in patients with persistent shock following acute myocardial infarction (MI) despite a patent infarct artery.
We examined data from TRIUMPH, a multicenter randomized clinical trial of the nitric oxide synthase inhibitor, L-N(G)-monomethyl-arginine, in patients with persistent vasopressor-dependent cardiogenic shock complicating acute MI at least 1 hour after established infarct-related artery patency. Patients who died within 30 days were compared with those who survived. Continuous variables were assessed using the Wilcoxon rank sum and categorical variables using the chi(2) test. Prespecified baseline variables were included in a multivariable logistic regression model to predict mortality. A second model incorporating baseline vasopressors and dosages and a third model including change in systolic blood pressure at 2 hours were also developed. Bootstrapping was used to assess the stability of model variables.
Of 396 patients, 180 (45.5%) died within 30 days. Systolic blood pressure (SBP), measured on vasopressor support, and creatinine clearance were significant predictors of mortality in all models. The number of vasopressors and norepinephrine dose were also predictors of mortality in the second model, but the latter was no longer significant when change in SBP at 2 hours was added as a covariate in the third model.
The SBP, creatinine clearance, and number of vasopressors are significant predictors of mortality in patients with persistent vasopressor-dependent cardiogenic shock following acute MI despite a patent infarct artery. These prognostic variables may be useful for risk-stratification and in selecting patients for investigation of additional therapies.
尽管梗死相关动脉通畅,但对于急性心肌梗死(MI)后持续性休克患者的生存预测因素知之甚少。
我们分析了TRIUMPH试验的数据,该试验是一项关于一氧化氮合酶抑制剂L-N(G)-单甲基精氨酸的多中心随机临床试验,研究对象为急性MI并发持续性血管升压药依赖的心源性休克患者,在梗死相关动脉通畅至少1小时后入组。比较30天内死亡的患者与存活患者。连续变量采用Wilcoxon秩和检验评估,分类变量采用卡方检验评估。将预先设定的基线变量纳入多变量逻辑回归模型以预测死亡率。还建立了包含基线血管升压药及其剂量的第二个模型,以及包含2小时时收缩压变化的第三个模型。采用自抽样法评估模型变量的稳定性。
396例患者中,180例(45.5%)在30天内死亡。在血管升压药支持下测得的收缩压(SBP)和肌酐清除率在所有模型中都是死亡率的显著预测因素。血管升压药的数量和去甲肾上腺素剂量在第二个模型中也是死亡率的预测因素,但在第三个模型中加入2小时时SBP的变化作为协变量后,后者不再显著。
对于急性MI后尽管梗死相关动脉通畅但仍存在持续性血管升压药依赖的心源性休克患者,SBP、肌酐清除率和血管升压药的数量是死亡率的显著预测因素。这些预后变量可能有助于进行风险分层以及选择患者进行其他治疗的研究。